Recent News

• 08.10.2026 - AIM ImmunoTech Reports Second Quarter 2026 Financial Results and Highlights Significant Operational Execution Advancing Ampligen® Toward Planned Phase 3 Development in Pancreatic Cancer
• 08.03.2026 - AIM ImmunoTech Ahead of Schedule on ‘Last Dose’ DURIPANC Critical Clinical Inflection Point
• 07.07.2026 - AIM ImmunoTech Announces Release of New CEO Corner Segment Highlighting Growing Momentum Across Pancreatic Cancer Program
• 06.24.2026 - AIM ImmunoTech Accelerates Toward Potential Pivotal Pancreatic Cancer Program as Ampligen Continues to Advance Through Key Clinical Milestones
• 06.22.2026 - AIM ImmunoTech to Present in the Webull Corporate Connect Webinar Series
• 06.18.2026 - AIM ImmunoTech Achieves Clinical Milestone as Final Subject Receives First Dose in Phase 2 DURIPANC Study in Metastatic Pancreatic Cancer
• 06.15.2026 - AIM ImmunoTech Regains NYSE American Compliance, Company Resolves Stockholder Equity Deficiency
• 02.11.2025 - AIM ImmunoTech Releases Virtual Investor “What This Means Segment”
• 02.11.2025 - AIM ImmunoTech announces that it will not proceed with an offering pursuant to its Registration Statement on Form S-1 until after it files its Annual Report on Form 10-K for the fiscal year ended December 31, 2024
• 02.07.2025 - AIM ImmunoTech announces a planned follow-up clinical study evaluating a combination treatment of AIM’s Ampligen® and AstraZeneca’s FluMist® to address the recent avian influenza outbreaks

Recent Filings

• 08.07.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.06.2026 - 8-K Current report
• 08.05.2026 - 8-K Current report
• 07.16.2026 - 8-K Current report
• 07.09.2026 - S-8 Securities to be offered to employees in employee benefit plans
• 06.25.2026 - DEF 14A Other definitive proxy statements
• 06.24.2026 - 424B3 Prospectus [Rule 424(b)(3)]
• 06.23.2026 - EFFECT Notice of Effectiveness
• 06.18.2026 - 424B3 Prospectus [Rule 424(b)(3)]
• 06.18.2026 - S-1 General form for registration of securities under the Securities Act of 1933